317 related articles for article (PubMed ID: 32388292)
1. MSI as a predictive factor for treatment outcome of gastroesophageal adenocarcinoma.
van Velzen MJM; Derks S; van Grieken NCT; Haj Mohammad N; van Laarhoven HWM
Cancer Treat Rev; 2020 Jun; 86():102024. PubMed ID: 32388292
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of microsatellite-instability in gastric and gastroesophageal junction cancer patients undergoing neoadjuvant chemotherapy.
Haag GM; Czink E; Ahadova A; Schmidt T; Sisic L; Blank S; Heger U; Apostolidis L; Berger AK; Springfeld C; Lasitschka F; Jäger D; von Knebel Doeberitz M; Kloor M
Int J Cancer; 2019 Apr; 144(7):1697-1703. PubMed ID: 30499151
[TBL] [Abstract][Full Text] [Related]
3. Immuno-Oncology Biomarkers for Gastric and Gastroesophageal Junction Adenocarcinoma: Why PD-L1 Testing May Not Be Enough.
Weinberg BA; Xiu J; Hwang JJ; Shields AF; Salem ME; Marshall JL
Oncologist; 2018 Oct; 23(10):1171-1177. PubMed ID: 29703766
[TBL] [Abstract][Full Text] [Related]
4. Prognostic and predictive impact of sex in locally advanced microsatellite instability high gastric or gastroesophageal junction cancer: An individual patient data pooled analysis of randomized clinical trials.
Raimondi A; Kim YW; Kang WK; Langley RE; Choi YY; Kim KM; Nankivell MG; Randon G; Kook MC; An JY; Grabsch HI; Prisciandaro M; Nichetti F; Noh SH; Sohn TS; Kim S; Wotherspoon A; Morano F; Cunningham D; Lee J; Cheong JH; Smyth EC; Pietrantonio F
Eur J Cancer; 2024 May; 203():114043. PubMed ID: 38598921
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of immune-checkpoint inhibitors in metastatic gastric or gastroesophageal junction adenocarcinoma by patient subgroups: A systematic review and meta-analysis.
Kundel Y; Sternschuss M; Moore A; Perl G; Brenner B; Goldvaser H
Cancer Med; 2020 Oct; 9(20):7613-7625. PubMed ID: 32869544
[TBL] [Abstract][Full Text] [Related]
6. Pattern of recurrence and overall survival in esophagogastric cancer after perioperative FLOT and clinical outcomes in MSI-H population: the PROSECCO Study.
Nappo F; Fornaro L; Pompella L; Catanese S; Lavacchi D; Spallanzani A; Cappetta A; Puzzoni M; Murgioni S; Barsotti G; Tirino G; Pellino A; Vivaldi C; Strippoli A; Aprile G; Di Donato S; Mazza E; Prisciandaro M; Antonuzzo L; Zagonel V; Cascinu S; De Vita F; Lonardi S
J Cancer Res Clin Oncol; 2023 Aug; 149(9):6601-6611. PubMed ID: 36795195
[TBL] [Abstract][Full Text] [Related]
7. Advances in immuno-oncology biomarkers for gastroesophageal cancer: Programmed death ligand 1, microsatellite instability, and beyond.
Lin EM; Gong J; Klempner SJ; Chao J
World J Gastroenterol; 2018 Jul; 24(25):2686-2697. PubMed ID: 29991874
[TBL] [Abstract][Full Text] [Related]
8. Immunogenic characteristics of microsatellite instability-low esophagogastric junction adenocarcinoma based on clinicopathological, molecular, immunological and survival analyses.
Imamura Y; Toihata T; Haraguchi I; Ogata Y; Takamatsu M; Kuchiba A; Tanaka N; Gotoh O; Mori S; Nakashima Y; Oki E; Mori M; Oda Y; Taguchi K; Yamamoto M; Morita M; Yoshida N; Baba H; Mine S; Nunobe S; Sano T; Noda T; Watanabe M
Int J Cancer; 2021 Mar; 148(5):1260-1275. PubMed ID: 32997798
[TBL] [Abstract][Full Text] [Related]
9. MSI Analysis in Solid and Liquid Biopsies of Gastroesophageal Adenocarcinoma Patients: A Molecular Approach.
Boldrin E; Piano MA; Alfieri R; Mazza M; Vassallo L; Scapinello A; Pilati P; Curtarello M
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34298864
[TBL] [Abstract][Full Text] [Related]
10. Beyond the PD-L1 horizon: In search for a good biomarker to predict success of immunotherapy in gastric and esophageal adenocarcinoma.
Koemans WJ; Chalabi M; van Sandick JW; van Dieren JM; Kodach LL
Cancer Lett; 2019 Feb; 442():279-286. PubMed ID: 30419350
[TBL] [Abstract][Full Text] [Related]
11. [Localized MSI/dMMR gastric cancer patients, perioperative immunotherapy instead of chemotherapy: The GERCOR NEONIPIGA phase II study is opened to recruitment].
Cohen R; Pudlarz T; Garcia-Larnicol ML; Vernerey D; Dray X; Clavel L; Jary M; Piessen G; Zaanan A; Aparicio T; Louvet C; Tournigand C; Chibaudel B; Tougeron D; Guimbaud R; Benouna J; Adenis A; Sokol H; Borg C; Duval A; Svrcek M; André T
Bull Cancer; 2020 Apr; 107(4):438-446. PubMed ID: 32057467
[TBL] [Abstract][Full Text] [Related]
12. Recent Incidence Trend of Surgically Resected Esophagogastric Junction Adenocarcinoma and Microsatellite Instability Status in Japanese Patients.
Imamura Y; Watanabe M; Toihata T; Takamatsu M; Kawachi H; Haraguchi I; Ogata Y; Yoshida N; Saeki H; Oki E; Taguchi K; Yamamoto M; Morita M; Mine S; Hiki N; Baba H; Sano T
Digestion; 2019; 99(1):6-13. PubMed ID: 30554205
[TBL] [Abstract][Full Text] [Related]
13. Gastroesophageal cancer: Navigating the immune and genetic terrain to improve clinical outcomes.
Jones JO; Smyth EC
Cancer Treat Rev; 2020 Mar; 84():101950. PubMed ID: 31918022
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of sintilimab-based regimens against advanced gastric and gastroesophageal junction adenocarcinoma.
Wang Y; Zhao J; Yu H; Wang J; Zhang N; Cao B
J Cancer Res Ther; 2021 Nov; 17(5):1234-1240. PubMed ID: 34850772
[TBL] [Abstract][Full Text] [Related]
15. Concordance of microsatellite instability and mismatch repair status in paired biopsies and surgical specimens of resectable gastroesophageal adenocarcinoma: time for a call to action.
Fornaro L; Lonardi S; Catanese S; Nappo F; Pietrantonio F; Pellino A; Angerilli V; Signorini F; Salani F; Murgioni S; Neculaescu IA; Bruno R; Vivaldi C; Ricagno G; Masi G; Bergamo F; Ugolini C; Fassan M
Gastric Cancer; 2023 Nov; 26(6):958-968. PubMed ID: 37382783
[TBL] [Abstract][Full Text] [Related]
16. Pembrolizumab for treatment of advanced gastric and gastroesophageal junction adenocarcinoma.
Joshi SS; Maron SB; Catenacci DV
Future Oncol; 2018 Feb; 14(5):417-430. PubMed ID: 29094609
[TBL] [Abstract][Full Text] [Related]
17. Novel Targeted Therapies for Esophagogastric Cancer.
Maron SB; Catenacci DV
Surg Oncol Clin N Am; 2017 Apr; 26(2):293-312. PubMed ID: 28279470
[TBL] [Abstract][Full Text] [Related]
18. Results of docetaxel plus oxaliplatin (DOCOX) ± cetuximab in patients with metastatic gastric and/or gastroesophageal junction adenocarcinoma: results of a randomised Phase 2 study.
Richards D; Kocs DM; Spira AI; David McCollum A; Diab S; Hecker LI; Cohn A; Zhan F; Asmar L
Eur J Cancer; 2013 Sep; 49(13):2823-31. PubMed ID: 23747051
[TBL] [Abstract][Full Text] [Related]
19. Lgr5 and stem/progenitor gene expression in gastric/gastroesophageal junction carcinoma - significance of potentially retained stemness.
Yoon JY; Brezden-Masley C; Streutker CJ
BMC Cancer; 2020 Sep; 20(1):860. PubMed ID: 32894084
[TBL] [Abstract][Full Text] [Related]
20. FDA Approval Summary: Pembrolizumab for Recurrent Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing PD-L1.
Fashoyin-Aje L; Donoghue M; Chen H; He K; Veeraraghavan J; Goldberg KB; Keegan P; McKee AE; Pazdur R
Oncologist; 2019 Jan; 24(1):103-109. PubMed ID: 30120163
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
